<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Genomics</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>GC Genome plans $30M IPO to diversify genomic products, suppliers</title>
      <description>
        <![CDATA[GC Genome Corp. priced a Kosdaq offering of 4 million shares at ₩10,500 per share May 27, entailing a gross ₩42 billion (US$30.5 million) raise in early June. The Yongin, South Korea-based genomics subsidiary of GC Biopharma Corp. fixed its shares price to the top of its ₩9,000 to ₩15,000 price band May 27 after conducting demand forecasting on domestic and international institutional investors from May 19 to May 23.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720488</guid>
      <pubDate>Tue, 27 May 2025 16:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720488-gc-genome-plans-30m-ipo-to-diversify-genomic-products-suppliers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/DNA-NGS-genome-sequencing.webp?t=1588871366" type="image/png" medium="image" fileSize="527937">
        <media:title type="plain">DNA NGS genome sequencing</media:title>
      </media:content>
    </item>
    <item>
      <title>Proteomics study explores how protein changes influence disease</title>
      <description>
        <![CDATA[Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to assess the levels of 5,400 different proteins.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716292</guid>
      <pubDate>Mon, 13 Jan 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716292-proteomics-study-explores-how-protein-changes-influence-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Blood-samples-in-lab.webp?t=1736544739" type="image/jpeg" medium="image" fileSize="191543">
        <media:title type="plain">Blood samples in lab</media:title>
      </media:content>
    </item>
    <item>
      <title>All of Us: 413,000 genomes across ancestries, ages, socioeconomics </title>
      <description>
        <![CDATA[Since its founding by the National Institutes of Health (NIH), the scientists of the All of Us Research Program have set the goal to analyze the largest diversity of the genomic population in the country and end the under-representation of its different groups. The project has expanded the vision of several pathologies, discovered thousands of new genetic variants, redefined the risk genes for common diseases, and stratified them, uncovering eight different forms in the case of type 2 diabetes (T2D). Their results create a pathway for a new age of precision medicine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705727</guid>
      <pubDate>Fri, 23 Feb 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705727-all-of-us-413-000-genomes-across-ancestries-ages-socioeconomics</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/All-of-Us.webp?t=1708702102" type="image/jpeg" medium="image" fileSize="185347">
        <media:title type="plain">All of Us illustration</media:title>
        <media:description type="plain">Researchers improved existing polygenic risk scores using health records and ancestrally diverse genomic data. Credit: Darryl Leja, National Human Genome Research Institute.</media:description>
      </media:content>
    </item>
    <item>
      <title>Study probes cancer’s interconnections</title>
      <description>
        <![CDATA[The most comprehensive analysis of gene dependencies in cancer cells to date has identified 370 “highly enriched” drug targets in defined molecular backgrounds. This latest iteration of the Cancer Dependency Map, published in <em>Cancer Cell</em>, Jan. 11, 2024, builds on an earlier version published in 2019, which was based on 324 cell lines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704555</guid>
      <pubDate>Mon, 15 Jan 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704555-study-probes-cancers-interconnections</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NHGRI-Next-Generation-DNA-Sequencing.webp?t=1699457300" type="image/png" medium="image" fileSize="1324038">
        <media:title type="plain">A DNA double helix rests on a print-out illustration of the DNA  base pair letters A, T, C and G.</media:title>
        <media:description type="plain">Credit: Darryl Leja, National Human Genome Research Institute, NIH
</media:description>
      </media:content>
    </item>
    <item>
      <title>Whole genome sequencing improves outcomes in multiple tumor types</title>
      <description>
        <![CDATA[A landmark, real-world study in the U.K. has demonstrated that combining whole genome sequencing with clinical data enabled tailored cancer treatment and improved outcomes. At one health care center, having DNA sequence data led to changes from usual standard of care in 25% of cases.  “Mostly, [patients] got into clinical trials; some got medicines they wouldn’t have got. Others avoided medicines because their genetic make-up suggested that if they were exposed to the medicines, they would be at risk of harm,” said Mark Caulfield, professor of clinical pharmacology at Queen Mary University of London, who is co-author of a paper outlining the findings in <em>Nature Medicine</em>, Jan 11, 2024.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704520</guid>
      <pubDate>Fri, 12 Jan 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704520-whole-genome-sequencing-improves-outcomes-in-multiple-tumor-types</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NHGRI-Prescription-Pill-Bottle-with-DNA.webp?t=1685025495" type="image/png" medium="image" fileSize="607483">
        <media:title type="plain">Illustration of prescription pill bottle with DNA on the label.</media:title>
        <media:description type="plain">Credit: Ernesto del Aguila III, National Human Genome Research Institute, NIH</media:description>
      </media:content>
    </item>
    <item>
      <title>Omics studies reveal 'Google map' of Alzheimer’s disease</title>
      <description>
        <![CDATA[The broadest view of post-mortem brains in Alzheimer’s disease (AD) has unveiled the genome, transcriptome and epigenome alterations of this neurodegenerative condition. The coordinated research, directed by scientists at the Massachusetts Institute of Technology (MIT), also described new cellular pathways that could help the scientific community design new therapies. Four simultaneous studies published on Sept. 28, 2023, in <em>Cell</em>, presented a brain single-cell atlas of AD, exposed the damage that affects DNA, and described the processes that alter the microglia and dysregulate the epigenome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701634</guid>
      <pubDate>Thu, 05 Oct 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701634-omics-studies-reveal-google-map-of-alzheimers-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Alzheimers-illustration.webp?t=1604527274" type="image/png" medium="image" fileSize="407999">
        <media:title type="plain">Elderly hands holding broken brain structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Omics studies reveal 'Google map' of Alzheimer’s disease</title>
      <description>
        <![CDATA[The broadest view of post-mortem brains in Alzheimer’s disease (AD) has unveiled the genome, transcriptome and epigenome alterations of this neurodegenerative condition. The coordinated research, directed by scientists at the Massachusetts Institute of Technology (MIT), also described new cellular pathways that could help the scientific community design new therapies. Four simultaneous studies published on Sept. 28, 2023, in <em>Cell</em>, presented a brain single-cell atlas of AD, exposed the damage that affects DNA, and described the processes that alter the microglia and dysregulate the epigenome.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701539</guid>
      <pubDate>Thu, 05 Oct 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701539-omics-studies-reveal-google-map-of-alzheimers-disease</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Alzheimers-illustration.webp?t=1604527274" type="image/png" medium="image" fileSize="407999">
        <media:title type="plain">Elderly hands holding broken brain structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Machine learning tool Alphamissense analyzes human mutations to predict diseases</title>
      <description>
        <![CDATA[Proteome analysis with artificial intelligence has made it possible to create a catalog of all possible missense mutations in the human genome to predict diseases. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/701202</guid>
      <pubDate>Tue, 19 Sep 2023 10:35:48 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701202-machine-learning-tool-alphamissense-analyzes-human-mutations-to-predict-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>Machine learning tool Alphamissense analyzes human mutations to predict diseases</title>
      <description>
        <![CDATA[Proteome analysis with artificial intelligence has made it possible to create a catalog of all possible missense mutations in the human genome to predict diseases. The new Alphamissense tool from the technology company Google Deepmind, available online, will allow scientists to refine diagnoses and design more tailored treatment strategies for patients suffering from pathologies associated with these variants.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701027</guid>
      <pubDate>Tue, 19 Sep 2023 10:35:48 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701027-machine-learning-tool-alphamissense-analyzes-human-mutations-to-predict-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Digital-health-DNA-gene-therapy-research.webp?t=1686951391" type="image/jpeg" medium="image" fileSize="229766">
        <media:title type="plain">Art concept for gene therapy research</media:title>
      </media:content>
    </item>
    <item>
      <title>Spinocerebellar ataxia variants show vast heterogeneity</title>
      <description>
        <![CDATA[The phenotypic variety of spinocerebellar ataxias (SCAs) not caused by CAG repeat expansion (polyglutamine SCA) is greater than expected. A collaboration directed by scientists of the Paris Brain Institute described seven variants of this disorder in 756 individuals, observing that age at onset and progression by gene and variant can occur from childhood to late adulthood with very different forms of the disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/697923</guid>
      <pubDate>Wed, 14 Jun 2023 09:00:23 -0400</pubDate>
      <link>https://www.bioworld.com/articles/697923-spinocerebellar-ataxia-variants-show-vast-heterogeneity</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Genetic-brain-disorders-conceptual-3D-illustration.webp?t=1686753489" type="image/jpeg" medium="image" fileSize="318696">
        <media:title type="plain">Genetic brain disorders, conceptual 3D illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Rare diseases yield genomic secrets through new computational approach</title>
      <description>
        <![CDATA[By adapting computational methods for dealing with large volumes of data, and slimming down that data, researchers at the Icahn School of Medicine at Mount Sinai have discovered previously unknown genetic associations with 19 rare diseases, and validated three of those associations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/695291</guid>
      <pubDate>Mon, 20 Mar 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/695291-rare-diseases-yield-genomic-secrets-through-new-computational-approach</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/hoofbeats-zebras-awareness-ribbon.webp?t=1679068131" type="image/png" medium="image" fileSize="1340145">
        <media:title type="plain">Awareness ribbon with zebra pattern</media:title>
        <media:description type="plain">Sometimes, hoofbeats are zebras after all. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>Rare diseases yield genomic secrets through new computational approach</title>
      <description>
        <![CDATA[By adapting computational methods for dealing with large volumes of data, and slimming down that data, researchers at the Icahn School of Medicine at Mount Sinai have discovered previously unknown genetic associations with 19 rare diseases, and validated three of those associations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/695222</guid>
      <pubDate>Fri, 17 Mar 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/695222-rare-diseases-yield-genomic-secrets-through-new-computational-approach</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/hoofbeats-zebras-awareness-ribbon.webp?t=1679068131" type="image/png" medium="image" fileSize="1340145">
        <media:title type="plain">Awareness ribbon with zebra pattern</media:title>
        <media:description type="plain">Sometimes, hoofbeats are zebras after all. Credit: NIAID</media:description>
      </media:content>
    </item>
    <item>
      <title>Massive cell-free DNA trial for the detection of cancer completes enrollment</title>
      <description>
        <![CDATA[The largest study to date assessing the use of cell-free DNA (cfDNA) analysis to detect cancer in advance of symptoms has completed enrollment of 140,000 healthy volunteers. The study, being run in the U.K. National Health Service (NHS) by the charity Cancer Research UK (CRUK) and cfDNA diagnostics specialist Grail Inc., is using Grail’s Galleri test to look for cancer-specific methylation patterns in blood.]]>
      </description>
      <guid>http://www.bioworld.com/articles/521457</guid>
      <pubDate>Tue, 09 Aug 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/521457-massive-cell-free-dna-trial-for-the-detection-of-cancer-completes-enrollment</link>
    </item>
    <item>
      <title>Long in the making changes lead to tipping point in blood stem cells</title>
      <description>
        <![CDATA[Two studies published back to back in <em>Nature</em> have looked at the accumulation of mutations in blood-forming stem cells with age, gaining new insights into how the overall landscape of such cells changes across the lifespan. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/519406</guid>
      <pubDate>Fri, 03 Jun 2022 10:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/519406-long-in-the-making-changes-lead-to-tipping-point-in-blood-stem-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Red-blood-cells2-.webp?t=1645222235" type="image/png" medium="image" fileSize="377934">
        <media:title type="plain">Red blood cells </media:title>
      </media:content>
    </item>
    <item>
      <title>Study finds variants that increase risk of severe COVID-19</title>
      <description>
        <![CDATA[The world’s largest genomics study in patients with life-threatening COVID-19 infections has uncovered 16 new genetic variants associated with severe disease and drawn up a roadmap for research into new therapies and diagnostics. The research involved comparing the complete genome sequences of 7,491 patients admitted to 224 intensive care units in the U.K. against those of 48,400 participants in Genomics England’s 100,000 Genomes project, and of a further 1,630 people who had mild COVID-19. While some of the gene variants found in the Genomicc study affect the function of a protein, others influence the amount of the protein that is expressed. An example is mucin-1, where overexpression led to worse outcomes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/516703</guid>
      <pubDate>Mon, 07 Mar 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/516703-study-finds-variants-that-increase-risk-of-severe-covid-19</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/DNA-sequence-and-COVID-19-infection-virus-cells.webp?t=1705956779" type="image/png" medium="image" fileSize="454028">
        <media:title type="plain">DNA sequence and COVID-19 virus cells</media:title>
        <media:description type="plain">The genotyping assays technology produced COVID-19 variant results almost a week more quickly than traditional WGS methods.
</media:description>
      </media:content>
    </item>
    <item>
      <title>Biofidelity attracts $23M series A investment to launch lung cancer test</title>
      <description>
        <![CDATA[Cancer diagnostics company Biofidelity Ltd. reported a $23 million series A+ investment round, led by Octopus Ventures with participation from SBI Investment Co. Ltd. and existing investors. Funds will be used for the commercial launch of the company’s first commercial assay Asypre-Lung. The oncology panel is designed to detect DNA mutations from tissue or liquid biopsy quicker than current approaches like gene sequencing.]]>
      </description>
      <guid>http://www.bioworld.com/articles/515708</guid>
      <pubDate>Wed, 02 Feb 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/515708-biofidelity-attracts-23m-series-a-investment-to-launch-lung-cancer-test</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/02-02-Biofidelity-staff.webp?t=1643841106" type="image/png" medium="image" fileSize="1771080">
        <media:title type="plain">Group photo of Biofidelity staff</media:title>
        <media:description type="plain">Credit: Biofidelity Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Sema4 signals commitment to bring genomics to clinical practice with $623M Genedx acquisition</title>
      <description>
        <![CDATA[Sema4 Holdings Corp. sent a bold message to the market with a definitive agreement to acquire Genedx Inc. from Opko Health Inc. for $623 million. The deal comes as Sema4 winds down its COVID-19 testing by the end of March. The company has been one of the largest testing organizations in Connecticut since its first contract in May 2020, but has lately come under scrutiny because of an investment by Annie Lamont, the governor’s wife.]]>
      </description>
      <guid>http://www.bioworld.com/articles/515239</guid>
      <pubDate>Tue, 18 Jan 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/515239-sema4-signals-commitment-to-bring-genomics-to-clinical-practice-with-623m-genedx-acquisition</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/01-18-Sema4-testing.webp?t=1642547696" type="image/png" medium="image" fileSize="1028268">
        <media:title type="plain">Sema4 lab technician running COVID-19 samples</media:title>
        <media:description type="plain">Sema4 has been providing COVID-19 testing in Connecticut. Credit: Sema4 Holdings Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Top Med-tech Trends of 2021: Better therapy matching brings optimism to depression treatment</title>
      <description>
        <![CDATA[2021 may mark the beginning of a new phase in treatment of depression. While genetic matching of depression therapies to patients has been touted for a decade, meta-analyses have not supported claims of improved response rates with studies often finding that any improvements seen likely came from switching patients to guideline-recommended therapies rather than any insight from genetics.]]>
      </description>
      <guid>http://www.bioworld.com/articles/514474</guid>
      <pubDate>Tue, 21 Dec 2021 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/514474-top-med-tech-trends-of-2021-better-therapy-matching-brings-optimism-to-depression-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/12-21-Taliaz-Predictix-Genetics.webp?t=1640125633" type="image/png" medium="image" fileSize="1347547">
        <media:title type="plain">Patient using Predictix Genetics on tablet</media:title>
        <media:description type="plain"> A patient provides information for Taliaz Ltd.'s Predictix Genetics.</media:description>
      </media:content>
    </item>
    <item>
      <title>Color valuation reaches $4.6B with vibrant $100M series E</title>
      <description>
        <![CDATA[Color Health Inc. followed its rainbow to another pot of gold, collecting $100 million in a series E financing round led by Kindred Ventures and funds advised by T. Rowe Price Associates Inc. Returning funding round participants also included General Catalyst, the company’s long-time lead investor, Viking Global Investors and Emerson Collective. With the latest cash infusion, the company’s total funds raised to date reached $378 million and its valuation of $4.6 billion propelled it into the top dozen health care unicorns. Founded in 2017 as Color Genomics, the Burlingame, Calif.-based company has raised more than two-thirds of its total funding this year with today’s series E following the close of a $167 million series D round in January.]]>
      </description>
      <guid>http://www.bioworld.com/articles/513197</guid>
      <pubDate>Tue, 09 Nov 2021 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/513197-color-valuation-reaches-46b-with-vibrant-100m-series-e</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/11-9-Color-Genomics-kit.webp?t=1636497567" type="image/png" medium="image" fileSize="148975">
        <media:title type="plain">Color Health Inc.’s genomics kit.</media:title>
        <media:description type="plain">Color Health Inc.’s genomics kit.</media:description>
      </media:content>
    </item>
    <item>
      <title>Berry Oncology shows promising data on early screening for six cancers</title>
      <description>
        <![CDATA[Oncology genomic testing company Berry Oncology Corp.’s latest research results showed promising data for its Hifi platform-based technology, its CEO Jun Zhou said during the first International Biopharma Industry Week held in Shanghai. With the Hifi liquid biopsy test, users can receive early screening of six cancers, including liver cancer, lung cancer, gastric cancer, colorectal cancer, esophageal cancer, and pancreatic cancer, with an overall sensitivity of 87.6%, specificity of 99.1%, and overall tissue of origin precision in 82% of positive cancers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/512476</guid>
      <pubDate>Mon, 18 Oct 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/512476-berry-oncology-shows-promising-data-on-early-screening-for-six-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cell-under-magnifying-glass.webp?t=1611092780" type="image/png" medium="image" fileSize="453785">
        <media:title type="plain">Cancer cells under magnifying glass</media:title>
      </media:content>
    </item>
    <item>
      <title>My Next Health gathers $150M capital from private investment group</title>
      <description>
        <![CDATA[Precision medicine company My Next Health Inc. (MNH) has guaranteed a $150 million equity capital commitment from Global Emerging Market (GEM), a $3.4 billion Luxembourg-based private investment group. MNH was formed in May 2020 due to a merger between functional genomics company The DNA Company and digital therapeutics platform My Pain Sensei. The New York-based company is developing genomics-based health management applications that offer patients personalized genetic insights.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511802</guid>
      <pubDate>Mon, 27 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511802-my-next-health-gathers-150m-capital-from-private-investment-group</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/3D-dollar-sign.webp?t=1624487200" type="image/png" medium="image" fileSize="316216">
        <media:title type="plain">3D dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Berry Oncology raises nearly $100M to ramp up early cancer screening products</title>
      <description>
        <![CDATA[Berry Oncology Corp. raised $99.15 million in a series B1 financing round to expand in the early cancer screening industry as it is seeing a growing demand in the sector. This brings the total capital raised to what it says is “the highest level in China’s early cancer screening industry.” The round was led by China Merchants Capital Management Co. Ltd., along with existing investors Qiming Venture Partners and Legend Capital.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511212</guid>
      <pubDate>Wed, 08 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511212-berry-oncology-raises-nearly-100m-to-ramp-up-early-cancer-screening-products</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Cancer-cells-pic.webp?t=1591653278" type="image/png" medium="image" fileSize="432362">
        <media:title type="plain">Digital cancer cells illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>NIH collaborates on test predictive of peripheral nerve sheath tumor occurrence</title>
      <description>
        <![CDATA[The U.S. National Institutes of Health had its hands full with the Rapid Acceleration of Diagnostics (RADx) program as the COVID-19 pandemic unwound, but the agency’s other work on diagnostics is bearing fruit. NIH said Aug. 31 that its collaboration with an academic research institute has led to development of a test that predicts which patients suffering from neurofibromatosis will develop cancers with metastatic potential.]]>
      </description>
      <guid>http://www.bioworld.com/articles/511097</guid>
      <pubDate>Fri, 03 Sep 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/511097-nih-collaborates-on-test-predictive-of-peripheral-nerve-sheath-tumor-occurrence</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Genetic-engineering-DNA-RNA.webp?t=1588872625" type="image/png" medium="image" fileSize="536310">
        <media:title type="plain">DNA illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Genome Medical lands combination punch with Genematters acquisition, $60M series C</title>
      <description>
        <![CDATA[Genome Medical Holding Co. put its competitors on notice with two big moves designed to position the company as a leader in genetic testing and virtual genomic care. The company acquired Genematters LLC, a provider of telegenetics counseling, and closed a $60 million series C fundraising round. Together, the moves stand to significantly expand Genome Medical&rsquo;s digital infrastructure and clinical expertise in genetics services.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510914</guid>
      <pubDate>Mon, 30 Aug 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510914-genome-medical-lands-combination-punch-with-genematters-acquisition-60m-series-c</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/DNA-dollars.webp?t=1588782408" type="image/png" medium="image" fileSize="377807">
        <media:title type="plain">DNA, dollars illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Genieus builds neurodegenerative diseases platform to develop diagnostics, personalized medicines</title>
      <description>
        <![CDATA[PERTH, Australia &ndash; Bioinformatic and cell technology company Genieus Genomics Ltd. is using the power of the human genome to build a platform for neurodegenerative diseases to develop diagnostic tests for personalized medicines.]]>
      </description>
      <guid>http://www.bioworld.com/articles/510384</guid>
      <pubDate>Thu, 12 Aug 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/510384-genieus-builds-neurodegenerative-diseases-platform-to-develop-diagnostics-personalized-medicines</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/08-12-Genieus.webp?t=1628805138" type="image/png" medium="image" fileSize="1691267">
        <media:title type="plain">Desk with computer monitor displaying Genieus' software</media:title>
        <media:description type="plain">Deep integrated genomics platform (DIGAP). Credit: Genieus Genomics Ltd. </media:description>
      </media:content>
    </item>
    <item>
      <title>10x Genomics releases new high-throughput single-cell analysis platform</title>
      <description>
        <![CDATA[10x Genomics Inc. launched its latest platform for single-cell analysis, the Chromium X Series, to cost-effectively &quot;enable massively large-scale experiments,&quot; according to the company.]]>
      </description>
      <guid>http://www.bioworld.com/articles/509372</guid>
      <pubDate>Thu, 15 Jul 2021 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/509372-x-genomics-releases-new-high-throughput-single-cell-analysis-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/07-14-10x-Chromium-X.webp?t=1626295104" type="image/png" medium="image" fileSize="727693">
        <media:title type="plain">Chromium X product image</media:title>
        <media:description type="plain">Chromium X for single-cell analysis. Credit: 10x Genomics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>10x Genomics releases new high-throughput single-cell analysis platform</title>
      <description>
        <![CDATA[10x Genomics Inc. launched its latest platform for single-cell analysis, the Chromium X Series, to cost-effectively &quot;enable massively large-scale experiments,&quot; according to the company. The system cuts the cost of single-cell analysis 83%, from 12 cents to 2 cents per cell, a significant step toward reducing the costs low enough to make genomic sequencing widely available.]]>
      </description>
      <guid>http://www.bioworld.com/articles/509322</guid>
      <pubDate>Wed, 14 Jul 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/509322-x-genomics-releases-new-high-throughput-single-cell-analysis-platform</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/07-14-10x-Chromium-X.webp?t=1626295104" type="image/png" medium="image" fileSize="727693">
        <media:title type="plain">Chromium X product image</media:title>
        <media:description type="plain">Chromium X for single-cell analysis. Credit: 10x Genomics Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>GE Healthcare collaborates with Sophia Genetics to better match patients to cancer treatments</title>
      <description>
        <![CDATA[GE Healthcare and Sophia Genetics SA partnered to develop new artificial intelligence (AI)-powered analytics and workflow solutions to improve patient matching with cancer therapies. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/509036</guid>
      <pubDate>Tue, 06 Jul 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/509036-ge-healthcare-collaborates-with-sophia-genetics-to-better-match-patients-to-cancer-treatments</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Doctor-and-patient.webp?t=1589836634" type="image/png" medium="image" fileSize="409596">
        <media:title type="plain">Doctor and patient consultation</media:title>
      </media:content>
    </item>
    <item>
      <title>Exome study identifies new genetic influences on weight</title>
      <description>
        <![CDATA[An exome sequencing study of more than 600,000 individuals of European and mixed American ancestry has identified more than a dozen genes, including five brain-expressed G protein-coupled receptors, that were associated with body mass index.]]>
      </description>
      <guid>http://www.bioworld.com/articles/508895</guid>
      <pubDate>Fri, 02 Jul 2021 11:30:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/508895-exome-study-identifies-new-genetic-influences-on-weight</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/obesity-weight.webp?t=1589291306" type="image/png" medium="image" fileSize="227065">
        <media:title type="plain">Tape measure wrapped around feet on scale</media:title>
      </media:content>
    </item>
    <item>
      <title>Investment in Ariel genetics platform just the beginning says MCI</title>
      <description>
        <![CDATA[TORONTO &ndash; An initial investment of $250,000 by MCI Onehealth Technologies Inc. could just be the beginning for Ariel Precision Medicine Inc. and an artificial intelligence-fueled platform that uses genetic and clinical data to identify early symptoms of chronic disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/507281</guid>
      <pubDate>Wed, 19 May 2021 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/507281-investment-in-ariel-genetics-platform-just-the-beginning-says-mci</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2021/05-19-MCI-Ariel-risk-factors.webp?t=1621457470" type="image/png" medium="image" fileSize="211975">
        <media:title type="plain">Illustration of person surrounded by risk factor icons</media:title>
        <media:description type="plain">Ariel Precision’s AI-powered Advance Platform combines deep genetic sequencing with advanced analytics to test for diseases such as pancreatitis.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
